Image

    Azithromycin With Nitazoxanide, Hydroxychloroquine or Ivermectin, With or Without Dutasteride, for Early Stage COVID-19: An Open-Label Prospective Observational Study in Males With Mild-to-Moderate COVID-19 (The Pre-AndroCoV Male Trial)

    October 2020 in “ Research Square (Research Square) ”
    Flavio Cadegiani, Andy Goren, Carlos Gustavo Wambier, J. Philip McCoy

    Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.

    Studysummary This study observed that males with androgenetic alopecia using dutasteride showed significantly improved COVID-19 outcomes, including shorter duration of symptoms and viral shedding, compared to those not using it and non-AGA males.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on researchsquare.com →
    Discuss this study in the Community →

    Related research 3

    1. Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin, or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients bioRxiv (Cold Spring Harbor Laboratory) · 2020
    2. Azithromycin With Nitazoxanide, Hydroxychloroquine or Ivermectin, With or Without Dutasteride, for Early Stage COVID-19: An Open-Label Prospective Observational Study in Males With Mild-to-Moderate COVID-19 (The Pre-AndroCoV Male Trial) Research Square (Research Square) · 2020
    3. Azithromycin With Nitazoxanide, Hydroxychloroquine or Ivermectin, With or Without Dutasteride, for Early Stage COVID-19: An Open-Label Prospective Observational Study in Males With Mild-to-Moderate COVID-19 (The Pre-AndroCoV Male Trial) Research Square (Research Square) · 2020